Study of the Plasma and Urinary cfDNA of in Kidney Transplant Patients
Launched by POULET GEOFFROY · Apr 2, 2025
Trial Information
Current as of July 04, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how to detect kidney transplant rejection by examining DNA from the blood and urine of kidney transplant patients. When a transplant is rejected, the body releases DNA from the donor kidney into the bloodstream. Researchers want to see if they can use a new technology to measure this DNA accurately, which could help identify and understand transplant rejection earlier.
To be eligible for this study, participants must be kidney transplant recipients who are suspected of having a rejection episode and need a specific test called a renal biopsy. Unfortunately, people with certain cognitive or mental health issues, or those unable to give their consent, cannot participate. If you join the study, you can expect to provide blood and urine samples, which will help researchers learn more about how to monitor transplant health. This trial aims to improve the care for kidney transplant patients by offering better ways to detect when their transplant is in trouble.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients living with a kidney transplant
- • Admitted for suspected transplant rejection requiring a renal biopsy (RBB) as an indication
- Exclusion Criteria:
- • Patients with cognitive and mental disorders rendering them unable to express their non-opposition to participation in the study
- • Not covered by a social security system.
- • Under guardianship or guardianship, or under legal protection.
- • Patients who have expressed their refusal to participate in the study
About Poulet Geoffroy
Poulet Geoffroy is a leading clinical trial sponsor dedicated to advancing medical research and enhancing patient care through innovative therapeutic solutions. With a strong emphasis on collaboration and integrity, the organization orchestrates and manages clinical trials across various therapeutic areas, ensuring compliance with regulatory standards and ethical guidelines. Leveraging a robust network of healthcare professionals and research institutions, Poulet Geoffroy is committed to delivering high-quality data that supports the development of safe and effective treatments, ultimately aiming to improve health outcomes for diverse patient populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Rouen, , France
Patients applied
Trial Officials
Geoffroy GP POULET, PhD
Study Director
CGenetix
TRISTAN DE NATTES, MEDICAL DOCTOR
Principal Investigator
CHU ROUEN UNIVERSITY
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported